Oxaliplatin
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Oxaliplatin: From Colorectal Cancer to Malignant Pleural Mesothelioma
One-Sentence Summary
Oxaliplatin is a third-generation platinum-based chemotherapeutic agent, globally established as the backbone of FOLFOX/XELOX regimens for colorectal cancer treatment. The TxGNN model predicts it may be effective for malignant pleural mesothelioma (MPM), with 5 clinical trials and 20 publications currently supporting this direction — including two completed Phase 2 trials directly testing oxaliplatin-based combinations in MPM.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Colorectal cancer (global standard of care; FOLFOX/XELOX backbone) |
| Predicted New Indication | Malignant Pleural Mesothelioma |
| TxGNN Prediction Score | 99.68% |
| Evidence Level | L2 |
| Philippines Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Oxaliplatin is a platinum analogue that exerts its anticancer effect by forming bulky DNA intrastrand and interstrand crosslinks — primarily GG-intrastrand adducts — which block DNA replication and transcription, ultimately triggering apoptosis. Unlike cisplatin, oxaliplatin’s adducts are not recognized by mismatch repair (MMR) proteins, giving it a distinct resistance profile and complementary activity to other platinum agents.
Malignant pleural mesothelioma is a rare but aggressive cancer of the pleural lining, strongly associated with asbestos exposure. MPM cells frequently harbor defects in DNA damage repair pathways — including ERCC1 downregulation and BAP1/NF2 mutations — which impair the cell’s ability to remove platinum-DNA adducts, theoretically increasing sensitivity to oxaliplatin. Combining oxaliplatin with antimetabolites such as gemcitabine (GemOx regimen) or raltitrexed creates a mechanistic synergy: oxaliplatin disrupts DNA integrity while antimetabolites block nucleotide synthesis, attacking tumor cells on two complementary fronts.
The clinical rationale is further reinforced by the emergence of intraperitoneal/intracavitary delivery strategies. HIPEC (Hyperthermic Intraperitoneal Chemotherapy) and PIPAC (Pressurized IntraPeritoneal Aerosol Chemotherapy) with oxaliplatin exploit the peritoneal-plasma barrier to achieve local drug concentrations 10–20× higher than systemic delivery, potentially overcoming the modest systemic response rates historically observed in MPM. Multiple Phase 2 trials, including one completed study with 29 patients (NCT00859469), have demonstrated measurable activity of oxaliplatin-based regimens in MPM, validating the TxGNN model’s high-confidence prediction.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00859469 | Phase 2 | Completed | 29 | Direct evaluation of Oxaliplatin (Eloxatin®) + Gemcitabine as first- or second-line chemotherapy for malignant pleural or peritoneal mesothelioma; assesses objective response rate |
| NCT00996385 | Phase 2 | Unknown | 29 | Bortezomib (Velcade) + Oxaliplatin (Eloxatin) in previously treated pleural or peritoneal mesothelioma; 6-cycle maximum, QoL and CT response assessed every 2 cycles |
| NCT03210298 | N/A | Unknown | 1,000 | Multicenter international registry of PIPAC/PITAC procedures for malignant pleural and peritoneal diseases; provides real-world safety data for intraperitoneal oxaliplatin |
Note: NCT06310473 (esophagogastric junction cancer) and NCT05107674 (NX-1607 Phase 1) were excluded as they are not directly relevant to MPM — likely database retrieval artifacts where oxaliplatin appears as a background chemotherapy.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12525529 | 2003 | Phase II | J Clin Oncol | Raltitrexed + Oxaliplatin in 70 MPM patients (55 chemo-naive, 15 pretreated); overall response rate reported; established this combination as active in MPM |
| 14609447 | 2003 | Phase II Multicenter | Clin Lung Cancer | Gemcitabine 1000 mg/m² + Oxaliplatin 80 mg/m² (days 1 & 8, 21-day cycle) in 25 MPM patients; efficacy and safety profile evaluated |
| 11989592 | 2001 | Phase I/II | Tumori | Pilot study of Oxaliplatin + Raltitrexed in inoperable MPM; preliminary activity signal following Phase I dose-finding |
| 15639727 | 2005 | Phase II | Lung Cancer | Vinorelbine 30 mg/m² (days 1, 8) + Oxaliplatin 130 mg/m² (day 1) in untreated MPM; 24% prior response rate with single-agent vinorelbine used as rationale |
| 19091133 | 2008 | Retrospective Cohort | J Occup Med Toxicol | Gemcitabine ± Oxaliplatin in pemetrexed-pretreated MPM patients; real-world second-line efficacy and tolerability assessment |
| 15893013 | 2005 | Phase II | Lung Cancer | Raltitrexed + Oxaliplatin as second-line therapy in 14 MPM patients; trial closed early due to absence of objective responses (disease stabilization in 4/14); important negative result |
| 10930799 | 2000 | Phase II Experience | Eur J Cancer | Institut Gustave Roussy 9-year experience in 163 mesothelioma patients across 7 trials; Raltitrexed-Oxaliplatin combination highlighted as a step forward |
| 31455014 | 2019 | Review | Int J Mol Sci | Cisplatin, oxaliplatin, and pemetrexed investigated for immunomodulatory capacity in MPM; supports rational design of oxaliplatin + immune checkpoint inhibitor combinations |
| 37359920 | 2023 | Systematic Review | Indian J Surg Oncol | PRISMA-guided systematic review of HIPEC protocols for peritoneal mesothelioma; oxaliplatin among agents reviewed for locoregional delivery |
| 12610498 | 2003 | Narrative Review | Br J Cancer | Comprehensive review of MPM chemotherapy including all Phase 2–3 trials published up to 2003; contextualizes oxaliplatin-based regimen results within the broader treatment landscape |
Philippines Market Information
Oxaliplatin currently has no registered products with the Philippine FDA (FDA Philippines). There are 0 active licenses on file.
This does not preclude clinical use under compassionate/expanded access pathways or institutional importation, but any formal repurposing program would require a new market authorization application.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic — Platinum analogue (3rd generation) |
| Myelosuppression Risk | Moderate — neutropenia and thrombocytopenia reported; generally less nephrotoxic than cisplatin but myelosuppression monitoring required |
| Emetogenicity Classification | Moderate to High — prophylactic antiemetic regimen (5-HT3 antagonist + dexamethasone) recommended |
| Monitoring Items | CBC with differential (before each cycle), serum creatinine and eGFR, liver function tests, neurological assessment (peripheral neuropathy grading — the dose-limiting toxicity of oxaliplatin) |
| Handling Protection | Must follow cytotoxic drug handling regulations; cold-exposure precaution recommended post-infusion (oxaliplatin induces acute cold-triggered dysesthesia) |
Safety Considerations
Safety data (TFDA package insert warnings, contraindications, and drug-drug interaction records) were not retrievable for this Evidence Pack. The primary known clinical concern unique to oxaliplatin — not shared with other platinum agents — is cumulative peripheral sensory neuropathy, which is both acute (cold-triggered, reversible) and chronic (dose-dependent, potentially irreversible at cumulative doses >850 mg/m²).
Please refer to the originator package insert (Eloxatin®, Sanofi) and current clinical guidelines for full safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Two completed Phase 2 trials (NCT00859469; Fizazi et al., JCO 2003) directly tested oxaliplatin-based regimens in MPM, establishing measurable activity — this meets the L2 threshold. The mechanistic basis (platinum-DNA adduct formation in a DNA-repair-deficient tumor) is well-grounded, and the emerging HIPEC/PIPAC intraperitoneal delivery route offers a pharmacokinetically favorable path for locoregional MPM control. However, oxaliplatin is not currently registered in the Philippines, and key safety data from the Philippine FDA package insert is unavailable.
To proceed, the following is needed:
- Mechanism of Action data: Retrieve full MOA and pharmacokinetic profile from DrugBank API (flagged as DG002 High priority)
- Philippine FDA package insert / safety dossier: Download and parse TFDA or originator SmPC PDF to fulfill DG001 (Blocking — required before S1 safety evaluation)
- Subtype-stratified evidence: Existing MPM trials rarely report oxaliplatin efficacy by histological subtype (epithelioid vs. sarcomatoid); a systematic search for subtype-specific outcomes would sharpen the evidence base
- Market access pathway: Identify Philippine FDA regulatory pathway for new indication filing or compassionate use authorization, given zero current registrations
- Peripheral neuropathy risk management plan: Cumulative neurotoxicity is the primary dose-limiting concern in any MPM treatment protocol using oxaliplatin; a formal monitoring and dose-modification protocol should be defined before clinical use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.